Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates in Dallas.
Por vez primera, unos científicos han captado un ciclón polar en el planeta Urano. Examinando las ondas de radio emitidas por el planeta gigante, detectaron el fenómeno en el polo norte del planeta. Lo descubierto parece demostrar que existe un rasgo común a todo …
Valiéndose de un algoritmo de inteligencia artificial, unos investigadores han identificado un nuevo antibiótico capaz de eliminar un tipo de bacteria responsable de muchas infecciones resistentes a los medicamentos. El logro es obra de un equipo integrado, entre otros, por Ga …
Noticias de la actualidad científica y tecnológica del 29 de mayo de 2023. …
AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
Spectros Medical Devices has pioneered a groundbreaking technology for monitoring the health of transplanted tissues in post-cancer and trauma reconstruction surgery, specifically in the highly specialized field of reconstructive micro-surgery.
Spectros Medical Devices Pioneers Tissue Monitoring Technology Read More »
Freudenberg Medical, a global CDMO for finished medical devices, components, and minimally invasive solutions, has implemented virtual reality training for employees working in catheter production at operations in Ireland and the United States.
Freudenberg Medical Utilizes VR Training in Catheter Manufacturing Read More »
Philogen S.p.A. announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD.
Philogen Announces Clinical Trial Collaboration with MSD Read More »
Nykode Therapeutics ASA announced that it has expanded the clinical collaboration and supply agreement with Roche to cover evaluation of VB10.16, Nykode’s wholly owned off-the-shelf therapeutic cancer vaccine candidate, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer who have progressed on pembrolizumab plus chemotherapy +/- bevacizumab as first line treatment.
IRLAB Therapeutics AB announced that the company will participate at Redeye Growth Day 2023 on Thursday, June 1, 2023, in Stockholm, Sweden.
IRLAB to present at Redeye Growth Day 2023 in Stockholm on June 1, 2023 Read More »
